ImmunoPrecise Antibodies Ltd. Quarterly Research And Development Expense in CAD from Q3 2022 to Q4 2023

Taxonomy & unit
ifrs-full: CAD
Summary
ImmunoPrecise Antibodies Ltd. quarterly/annual Research And Development Expense history and growth rate from Q3 2022 to Q4 2023.
  • ImmunoPrecise Antibodies Ltd. Research And Development Expense for the quarter ending January 31, 2024 was CA$1M, a 36% decline year-over-year.
  • ImmunoPrecise Antibodies Ltd. annual Research And Development Expense for 2022 was CA$12.3M, a 60.3% increase from 2021.
  • ImmunoPrecise Antibodies Ltd. annual Research And Development Expense for 2021 was CA$7.66M, a 288% increase from 2020.
  • ImmunoPrecise Antibodies Ltd. annual Research And Development Expense for 2020 was CA$1.97M, a 343% increase from 2019.
Research And Development Expense, Quarterly (CAD)
Research And Development Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2023 1M -562K -36% Nov 1, 2023 Jan 31, 2024 6-K 2024-03-14
Q3 2023 1.04M -3.97M -79.3% Aug 1, 2023 Oct 31, 2023 6-K/A 2024-02-15
Q4 2022 1.56M Nov 1, 2022 Jan 31, 2023 6-K 2024-03-14
Q3 2022 5M Aug 1, 2022 Oct 31, 2022 6-K/A 2024-02-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.